Acetylcholinesterase inhibitors are recommended as first‐line treatment in MG as they increase the amount of acetylcholine in the synaptic cleft, thus improving neuromuscular transmission [15, 16, 17]. This evidence concerns the gene ACHE and myasthenia gravis.